Provided by Tiger Fintech (Singapore) Pte. Ltd.

Altimmune, Inc.

5.54
-0.1800-3.15%
Volume:1.30M
Turnover:7.28M
Market Cap:426.66M
PE:-4.14
High:5.66
Open:5.57
Low:5.50
Close:5.72
Loading ...

FDA APPROVES LUMAKRAS® (SOTORASIB) IN COMBINATION WITH VECTIBIX® (PANITUMUMAB) FOR CHEMOREFRACTORY KRAS G12C-MUTATED METASTATIC COLORECTAL CANCER

PR Newswire
·
17 Jan

Stifel Initiates Altimmune at Buy With $18 Price Target

MT Newswires Live
·
08 Jan

Evercore ISI Keeps Their Buy Rating on Altimmune (ALT)

TIPRANKS
·
08 Jan

Altimmune Inc : Stifel Initiates Coverage With Buy Rating; Price Target $18

THOMSON REUTERS
·
08 Jan

Innovative Breakthrough in Metabolic Disease Treatment: Annabel Samimy’s Buy Rating on Altimmune’s Pemvidutide

TIPRANKS
·
08 Jan

Altimmune initiated with a Buy at Stifel

TIPRANKS
·
08 Jan

BUZZ-Viking set to double in 'challenging' year for obesity drug developers

Reuters
·
01 Jan

Low Market Cap Cryptos Offering High-Risk, High-Reward Opportunities!

CoinMarketCap
·
29 Dec 2024

Assembly Biosciences Reports Interim Phase 1b Results from Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 in Chronic Hepatitis B

GlobeNewswire
·
26 Dec 2024

Sixty Degrees Pharmaceuticals and Tufts Medical Center Announce Patent License Agreement to Advance Development of Tafenoquine for Babesiosis Treatment and Prevention

GlobeNewswire
·
23 Dec 2024

B.Riley Financial Keeps Their Buy Rating on Altimmune (ALT)

TIPRANKS
·
21 Dec 2024

MTVA: Compelling Data for DA-1241 in Phase 2a MASH Trial…

Zacks Small Cap Research
·
20 Dec 2024

FACTBOX-Weight-loss drug developers line up to tap market worth $150 billion

Reuters
·
20 Dec 2024

Shares of Viking Therapeutics up 4.2%, Amgen up 1%

THOMSON REUTERS
·
20 Dec 2024

Weight Loss Drug Developers Rise After Novo Nordisk's Obesity Drug Cagrisema Achieves Lower Weight Loss Than Expected

THOMSON REUTERS
·
20 Dec 2024

BUZZ-Weight-loss drug developers gain after Novo's obesity drug underperforms in study

Reuters
·
20 Dec 2024